NCT00972335

Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

A Phase II Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: SCRI Development Innovations, LLC · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this multicenter, Phase II trial, the investigators plan to evaluate the activity of the combination of bevacizumab and everolimus in patients with recurrent, progressive meningioma following maximal treatment with surgical resection and local radiation therapy. Although these patients are relatively rare, there is currently no established standard of treatment for a disease that causes a great deal of morbidity, and that is eventually fatal.

Conditions

• Intracranial Meningioma

Interventions

Type	Name	Description
DRUG	Everolimus	This drug will be dosed at 10 mg orally DAILY for the duration of the study.
DRUG	Bevacizumab	This drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study.

Timeline

• Start date: 2010-01-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2009-09-04
• Last updated: 2021-11-10
• Results posted: 2015-06-04

Locations

7 sites across 1 country: United States